{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:33:25Z","timestamp":1788813205646,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:00:00Z","timestamp":1714348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:00:00Z","timestamp":1714348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ministero dell'Istruzione, dell'Universit\u00e0 e della Ricerca"},{"DOI":"10.13039\/100012990","name":"Universit\u00e0 degli Studi di Siena","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012990","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To evaluate the variables influencing the therapeutic choice toward oral versus subcutaneous semaglutide in a cohort of diabetic subjects.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively collected data of 292 patients followed at the Diabetes Unit of the University Hospital of Siena and the Hospital of Grosseto, who were prescribed oral (n\u2009=\u2009115) or subcutaneous (n\u2009=\u2009177) semaglutide between October 2021 and October 2022.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Oral semaglutide was preferentially prescribed in older subjects with longer disease duration in replacement of other antidiabetic drugs, while subcutaneous semaglutide was preferentially prescribed in add-on to metformin in subjects with higher body weight and BMI. After 6\u00a0months, both formulations significantly improved glycemic control and body weight, however injectable semaglutide showed a greater efficacy on A1c levels, weight loss, BMI and waist circumference reduction. No differences were found in terms of adverse events.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In our experience, injectable semaglutide is preferred in patients with excess weight and shorter disease duration, while the oral formulation was used later and especially after therapeutic failure of previous therapies. Follow-up data indicate similar tolerability and efficacy of both formulations, despite subcutaneous semaglutide demonstrated greater efficacy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s40618-024-02369-4","type":"journal-article","created":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T13:03:33Z","timestamp":1714395813000},"page":"2679-2690","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Real-world use of oral versus subcutaneous semaglutide in a cohort of type 2 diabetic patients: which option to which patient?"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7703-8216","authenticated-orcid":false,"given":"C.","family":"Formichi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Baronti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"de Gennaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cerrai Ceroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Nigi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Dotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,29]]},"reference":[{"issue":"sup2","key":"2369_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/00325481.2020.1798099","volume":"132","author":"SA Brunton","year":"2020","unstructured":"Brunton SA, Wysham CH (2020) GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date. Postgrad Med 132(sup2):3\u201314","journal-title":"Postgrad Med"},{"issue":"10193","key":"2369_CR2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Ryd\u00e9n L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394(10193):121\u2013130","journal-title":"Lancet"},{"issue":"13","key":"2369_CR3","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, \u00d6hman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF (2017) Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 377(13):1228\u20131239","journal-title":"N Engl J Med"},{"issue":"4","key":"2369_CR4","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375(4):311\u2013322","journal-title":"N Engl J Med"},{"issue":"4","key":"2369_CR5","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.numecd.2022.01.027","volume":"32","author":"E Mannucci","year":"2022","unstructured":"Mannucci E, Candido R, Delle Monache L, Gallo M, Giaccari A, Masini ML, Mazzone A, Medea G, Pintaudi B, Targher G, Trento M, Turchetti G, Lorenzoni V, Monami M (2022) Italian guidelines for the treatment of type 2 diabetes. Nutr Metab Cardiovasc Dis 32(4):770\u2013814","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2369_CR6","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","volume":"65","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, Rosas SE, Del Prato S, Mathieu C, Mingrone G, Rossing P, Tankova T, Tsapas A, Buse JB (2022) Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 65:1925\u20131966","journal-title":"Diabetologia"},{"issue":"2","key":"2369_CR7","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2337\/dc17-0417","volume":"41","author":"AJ Ahmann","year":"2018","unstructured":"Ahmann AJ, Capehorn M, Charpentier G, Dotta F, Henkel E, Lingvay I, Holst AG, Annett MP, Aroda VR (2018) Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label. Randomized Clin Trial Diabetes Care 41(2):258\u2013266","journal-title":"Randomized Clin Trial Diabetes Care"},{"issue":"5","key":"2369_CR8","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S2213-8587(17)30092-X","volume":"5","author":"B Ahr\u00e9n","year":"2017","unstructured":"Ahr\u00e9n B, Masmiquel L, Kumar H, Sargin M, Karsb\u00f8l JD, Jacobsen SH, Chow F (2017) Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol 5(5):341\u2013354","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"2369_CR9","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","volume":"5","author":"C Sorli","year":"2017","unstructured":"Sorli C, Harashima SI, Tsoukas GM, Unger J, Karsb\u00f8l JD, Hansen T, Bain SC (2017) Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol 5(4):251\u2013260","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"2369_CR10","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S2213-8587(17)30085-2","volume":"5","author":"VR Aroda","year":"2017","unstructured":"Aroda VR, Bain SC, Cariou B, Pileti\u010d M, Rose L, Axelsen M, Rowe E, DeVries JH (2017) Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol 5(5):355\u2013366","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"2369_CR11","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/S2213-8587(19)30311-0","volume":"7","author":"I Lingvay","year":"2019","unstructured":"Lingvay I, Catarig AM, Frias JP, Kumar H, Lausvig NL, le Roux CW, Thielke D, Viljoen A, McCrimmon RJ (2019) Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol 7(11):834\u2013844","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"2369_CR12","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","volume":"6","author":"RE Pratley","year":"2018","unstructured":"Pratley RE, Aroda VR, Lingvay I, L\u00fcdemann J, Andreassen C, Navarria A, Viljoen A (2018) Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol 6(4):275\u2013286","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"2369_CR13","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1210\/jc.2018-00070","volume":"103","author":"HW Rodbard","year":"2018","unstructured":"Rodbard HW, Lingvay I, Reed J, de la Rosa R, Rose L, Sugimoto D, Araki E, Chu PL, Wijayasinghe N, Norwood P (2018) Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized. Controlled Trial J Clin Endocrinol Metab 103(6):2291\u20132301","journal-title":"Controlled Trial J Clin Endocrinol Metab"},{"issue":"5","key":"2369_CR14","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/S2213-8587(19)30066-X","volume":"7","author":"B Zinman","year":"2019","unstructured":"Zinman B, Bhosekar V, Busch R, Holst I, Ludvik B, Thielke D, Thrasher J, Woo V, Philis-Tsimikas A (2019) Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 7(5):356\u2013367","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"19","key":"2369_CR15","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsb\u00f8ll T (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375(19):1834\u20131844","journal-title":"N Engl J Med"},{"issue":"9","key":"2369_CR16","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1111\/dom.14453","volume":"23","author":"VR Aroda","year":"2021","unstructured":"Aroda VR, Faurby M, Lophaven S, Noone J, Wolden ML, Lingvay I (2021) Insights into the early use of oral semaglutide in routine clinical practice: the IGNITE study. Diabetes Obes Metab 23(9):2177\u20132182","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"2369_CR17","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.2337\/dc19-0749","volume":"42","author":"VR Aroda","year":"2019","unstructured":"Aroda VR, Rosenstock J, Terauchi Y, Altuntas Y, Lalic NM, Morales Villegas EC, Jeppesen OK, Christiansen E, Hertz CL, Haluz\u00edk M (2019) PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care 42(9):1724\u20131732","journal-title":"Diabetes Care"},{"issue":"7","key":"2369_CR18","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S2213-8587(19)30192-5","volume":"7","author":"O Mosenzon","year":"2019","unstructured":"Mosenzon O, Blicher TM, Rosenlund S, Eriksson JW, Heller S, Hels OH, Pratley R, Sathyapalan T, Desouza C (2019) Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol 7(7):515\u2013527","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"2369_CR19","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S2213-8587(20)30075-9","volume":"8","author":"Y Yamada","year":"2020","unstructured":"Yamada Y, Katagiri H, Hamamoto Y, Deenadayalan S, Navarria A, Nishijima K, Seino Y (2020) Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2\/3a, randomised, controlled trial. Lancet Diabetes Endocrinol 8(5):377\u2013391","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"2369_CR20","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/S2213-8587(20)30074-7","volume":"8","author":"D Yabe","year":"2020","unstructured":"Yabe D, Nakamura J, Kaneto H, Deenadayalan S, Navarria A, Gislum M, Inagaki N (2020) Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial. Lancet Diabetes Endocrinol 8(5):392\u2013406","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"2369_CR21","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, Jeppesen OK, Lingvay I, Mosenzon O, Pedersen SD, Tack CJ, Thomsen M, Vilsb\u00f8ll T, Warren ML, Bain SC (2019) Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 381(9):841\u2013851","journal-title":"N Engl J Med"},{"key":"2369_CR22","unstructured":"European Medicines Agency (EMA) (2021) Human medicines highlights 2020. https:\/\/www.ema.europa.eu\/en\/news\/human-medicines-highlights-2020"},{"issue":"12","key":"2369_CR23","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1007\/s13300-023-01490-6","volume":"14","author":"ML Morieri","year":"2023","unstructured":"Morieri ML, Candido R, Frontoni S, Disoteo O, Solini A, Fadini GP (2023) Clinical features, cardiovascular risk profile, and therapeutic trajectories of patients with type 2 diabetes candidate for oral semaglutide therapy in the Italian specialist care. Diabetes Ther 14(12):2159\u20132172","journal-title":"Diabetes Ther"},{"key":"2369_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.645617","volume":"12","author":"JJ Meier","year":"2021","unstructured":"Meier JJ (2021) Efficacy of semaglutide in a subcutaneous and an oral formulation. Front Endocrinol (Lausanne) 12:645617","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"2369_CR25","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1111\/dom.13353","volume":"20","author":"B Ahr\u00e9n","year":"2018","unstructured":"Ahr\u00e9n B, Atkin SL, Charpentier G, Warren ML, Wilding JPH, Birch S, Holst AG, Leiter LA (2018) Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. Diabetes Obes Metab 20(9):2210\u20132219","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"2369_CR26","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1111\/dom.14054","volume":"22","author":"TK Thethi","year":"2020","unstructured":"Thethi TK, Pratley R, Meier JJ (2020) Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: the PIONEER programme. Diabetes Obes Metab 22(8):1263\u20131277","journal-title":"Diabetes Obes Metab"},{"key":"2369_CR27","unstructured":"World Population Review (2023). https:\/\/worldpopulationreview.com\/country-rankings\/median-age"},{"issue":"18","key":"2369_CR28","doi-asserted-by":"publisher","first-page":"6052","DOI":"10.3390\/jcm12186052","volume":"12","author":"R Candido","year":"2023","unstructured":"Candido R, Gaiotti S, Giudici F, Toffoli B, De Luca F, Velardi V, Petrucco A, Gottardi C, Manca E, Buda I, Fabris B, Bernardi S (2023) Real-world retrospective study into the effects of oral semaglutide (as a switchover or add-on therapy) in type 2 diabetes. J Clin Med 12(18):6052","journal-title":"J Clin Med"},{"issue":"9","key":"2369_CR29","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1111\/dom.14451","volume":"23","author":"A Tsapas","year":"2021","unstructured":"Tsapas A, Karagiannis T, Kakotrichi P, Avgerinos I, Mantsiou C, Tousinas G, Manolopoulos A, Liakos A, Malandris K, Matthews DR, Bekiari E (2021) Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Obes Metab 23(9):2116\u20132124","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"2369_CR30","doi-asserted-by":"publisher","first-page":"e001649","DOI":"10.1136\/bmjdrc-2020-001649","volume":"8","author":"JB Buse","year":"2020","unstructured":"Buse JB, Bode BW, Mertens A, Cho YM, Christiansen E, Hertz CL, Nielsen MA, Pieber TR (2020) Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial. BMJ Open Diabetes Res Care 8(2):e001649","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"3","key":"2369_CR31","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1111\/dom.15393","volume":"26","author":"S Furusawa","year":"2023","unstructured":"Furusawa S, Nomoto H, Yokoyama H, Suzuki Y, Tsuzuki A, Takahashi K, Miya A, Kameda H, Cho KY, Takeuchi J, Nagai S, Taneda S, Kurihara Y, Nakamura A, Atsumi T (2023) Glycaemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: a multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 2 study). Diabetes Obes Metab 26(3):961\u2013970","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"2369_CR32","doi-asserted-by":"publisher","first-page":"107","DOI":"10.4158\/CS-2019-0472","volume":"26","author":"AJ Garber","year":"2020","unstructured":"Garber AJ, Handelsman Y, Grunberger G, Einhorn D, Abrahamson MJ, Barzilay JI, Blonde L, Bush MA, DeFronzo RA, Garber JR, Garvey WT, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Perreault L, Rosenblit PD, Samson S, Umpierrez GE (2020) Consensus statement by the american association of clinical endocrinologists and american college of endocrinology on the comprehensive type 2 diabetes management algorithm\u20142020 executive summary. Endocr Pract 26(1):107\u2013139","journal-title":"Endocr Pract"},{"issue":"2","key":"2369_CR33","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/dom.14244","volume":"23","author":"K Boye","year":"2021","unstructured":"Boye K, Ross M, Mody R, Konig M, Gelhorn H (2021) Patients\u2019 preferences for once-daily oral versus once-weekly injectable diabetes medications: the REVISE study. Diabetes Obes Metab 23(2):508\u2013519","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"2369_CR34","doi-asserted-by":"publisher","first-page":"4114","DOI":"10.1007\/s12325-022-02181-7","volume":"39","author":"JH Shubrook","year":"2022","unstructured":"Shubrook JH, Radin M, Ali SN, Chubb B, DiPietrantonio K, Collings H, Wyn R, Smith M (2022) Preference for type 2 diabetes therapies in the United States: a discrete choice experiment. Adv Ther 39(9):4114\u20134130","journal-title":"Adv Ther"},{"issue":"7","key":"2369_CR35","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1007\/s11136-021-02808-2","volume":"30","author":"LS Matza","year":"2021","unstructured":"Matza LS, Cutts KN, Stewart KD, Norrbacka K, Garc\u00eda-P\u00e9rez LE, Boye KS (2021) Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes. Qual Life Res 30(7):2033\u20132043","journal-title":"Qual Life Res"},{"key":"2369_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.conctc.2022.100944","volume":"28","author":"Y Alhindi","year":"2022","unstructured":"Alhindi Y, Avery A (2022) The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP-1 RA comparators: a systematic review and network meta-analysis. Contemp Clin Trials Commun 28:100944","journal-title":"Contemp Clin Trials Commun"},{"key":"2369_CR37","doi-asserted-by":"publisher","DOI":"10.2337\/db22-127-LB","author":"MS Frazer","year":"2022","unstructured":"Frazer MS, Swift C, Leszko M, Sargent A, Buysman E, Alvarez SB, Noone J, Guevarra M (2022) 127-LB: Real-world A1C changes and prescribing provider types among T2DM patients initiating treatment with oral semaglutide. Diabetes. https:\/\/doi.org\/10.2337\/db22-127-LB","journal-title":"Diabetes"},{"issue":"2","key":"2369_CR38","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/apt.15316","volume":"50","author":"P Newsome","year":"2019","unstructured":"Newsome P, Francque S, Harrison S, Ratziu V, Van Gaal L, Calanna S, Hansen M, Linder M, Sanyal A (2019) Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and\/or obesity. Aliment Pharmacol Ther 50(2):193\u2013203","journal-title":"Aliment Pharmacol Ther"},{"key":"2369_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.645563","volume":"12","author":"MM Smits","year":"2021","unstructured":"Smits MM, Van Raalte DH (2021) Safety of semaglutide. Front Endocrinol (Lausanne) 12:645563","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"15","key":"2369_CR40","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2017.14752","volume":"318","author":"M Davies","year":"2017","unstructured":"Davies M, Pieber TR, Hartoft-Nielsen ML, Hansen OKH, Jabbour S, Rosenstock J (2017) Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. JAMA 318(15):1460\u20131470","journal-title":"JAMA"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-024-02369-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-024-02369-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-024-02369-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T13:10:38Z","timestamp":1729170638000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-024-02369-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,29]]},"references-count":40,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["2369"],"URL":"https:\/\/doi.org\/10.1007\/s40618-024-02369-4","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,29]]},"assertion":[{"value":"24 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"On behalf of all authors, the corresponding author states that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed were in accordance with the local ethical standards and with the Helsinki Declaration of 1964 and later versions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants"}},{"value":"For this type of study, no informed consent is required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}